Press release
Acral Lentiginous Melanoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Acral Lentiginous Melanoma Pipeline
Discover the latest drugs and treatment options in the Acral Lentiginous Melanoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Acral Lentiginous Melanoma Pipeline Outlook- https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Acral Lentiginous Melanoma Pipeline Report
• In May 2025, Medicenna Therapeutics Inc. announced a Phase 1/2 dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
• DelveInsight's Acral Lentiginous Melanoma Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Acral Lentiginous Melanoma treatment.
• The leading Acral Lentiginous Melanoma Companies such as Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
• Promising Acral Lentiginous Melanoma Pipeline Therapies such as Pembrolizumab (KEYTRUDA®), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.
Stay ahead with the most recent pipeline outlook for Acral Lentiginous Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acral Lentiginous Melanoma Treatment Drugs- https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Acral Lentiginous Melanoma Emerging Drugs Profile
• MDNA11: Medicenna Therapeutics, Inc.
MDNA11 is a long-acting IL-2 Superkine that has been fused with human recombinant albumin, which increases its half-life and minimizes dosing requirements without sacrificing efficacy and safety. This Superkine has been designed to preferentially bind the IL-2 beta receptor (IL-2Rβ) on immune cells and to become a powerful switch for activating and proliferating the immune cells needed to fight cancer. It is being developed specifically as a therapeutic for various solid tumors, potentially in combination with other immunotherapies. MDNA11 has the ability to preferentially stimulate cancer-fighting NK cells and naive CD8 cells instead of immuno-suppressive regulatory T cells, by 80 and 200 fold, respectively, when compared to native IL-2. It does so by specifically binding to IL-2Rβ. and begins a cascade of events that overcomes the immune-suppressing effects of cancer and activates the cancer-killing immune cells - including cytotoxic T cells, naive T cells, and natural killer cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Acral Lentiginous Melanoma.
The Acral Lentiginous Melanoma Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acral Lentiginous Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acral Lentiginous Melanoma Treatment.
• Acral Lentiginous Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acral Lentiginous Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acral Lentiginous Melanoma market
Explore groundbreaking therapies and clinical trials in the Acral Lentiginous Melanoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Acral Lentiginous Melanoma Drugs- https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Acral Lentiginous Melanoma Companies
Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
Acral lentiginous melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Acral Lentiginous Melanoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Unveil the future of Acral Lentiginous Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Acral Lentiginous Melanoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Acral Lentiginous Melanoma Pipeline Report
• Coverage- Global
• Acral Lentiginous Melanoma Companies- Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
• Acral Lentiginous Melanoma Pipeline Therapies- Pembrolizumab (KEYTRUDA®), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.
• Acral Lentiginous Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acral Lentiginous Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Acral Lentiginous Melanoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Acral Lentiginous Melanoma Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-pipeline-insight
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acral Lentiginous Melanoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4153008 • Views: …
More Releases from DelveInsight Business Research LLP
ALK+ NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approva …
DelveInsight's, "ALK+ NSCLC Pipeline Insight 2025" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK+ NSCLC pipeline landscape. It covers the ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Advanced Melanoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA …
DelveInsight's, "Advanced Melanoma Pipeline Insight 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape. It covers the Advanced Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Adenoid Cystic Carcinoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDM …
DelveInsight's, "Adenoid Cystic Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adenoid Cystic Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
HPK1 Inhibitors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "HPK1 inhibitors Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the HPK1 Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPK1 Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Acral
Chemotherapy Induced Acral Erythema Treatment Market | Exploring Current Trends …
Chemotherapy Induced Acral Erythema Treatment Market size was valued at USD 1.5 Billion in 2024 and is forecasted to grow at a CAGR of 7.1% from 2026 to 2033, reaching USD 2.8 Billion by 2033.
Chemotherapy Induced Acral Erythema Treatment Market Outlook and Investment Analysis
What is the current outlook of the Chemotherapy Induced Acral Erythema Treatment Market?
The Chemotherapy Induced Acral Erythema (CAAE) Treatment Market is witnessing significant growth due to the…
Chemotherapy-Induced Acral Erythema Market Giants Spending Is Going to Boom
The Global Chemotherapy-Induced Acral Erythema Market Report by Absolute Markets Insights contains the market strategy, market orientation, expert opinion and knowledgeable information. It is an in-depth study analyzing the current state of the Chemotherapy-Induced Acral Erythema Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Chemotherapy-Induced Acral Erythema Market…
Acral Lentiginous Melanoma Market Size, Opportunity, Analysis & Trends 2023-2033
Acral Lentiginous Melanoma Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years 2023-2033
Historical Years 2017-2022
Market Growth (2023-2033) 3.44%
The report offers a comprehensive analysis of the acral lentiginous melanoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report…
2023: Acral Lentiginous Melanoma Drugs Market to reach US$ 90 million in 2029
The Acral Lentiginous Melanoma Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status…
The Next Decade See Chemotherapy-Induced Acral Erythema Market Pushed Towards Ex …
According to latest research by Persistence Market Research, Chemotherapy-Induced Acral Erythema Market is set to witness steady growth during 2021-2031.
Increase in usage of chemotherapeutic agents due to increasing prevalence of cancers is the major growth driver of chemotherapy induced acral erythema treatment market.
Acral erythema is also known as hand-foot syndrome or palmoplantar erythrodysesthesia. Acryl erythema is a result of adverse drug reaction typically occur after several months of treatment with…
Global Acral lentiginous melanoma - Market Report Forecast to 2027
A melanoma that develops on the palms of the hands, the soles of the feet, or under the nails is known as acral lentiginous melanoma (ALM). The name "acral" comes from the Greek word "extremity," and it alludes to the appearance of this form of melanoma on the extremities. The term "lentiginous" refers to how melanoma spots are frequently significantly darker than the surrounding skin. ALM is the most frequent…
